Hostname: page-component-76fb5796d-9pm4c Total loading time: 0 Render date: 2024-04-27T18:54:18.867Z Has data issue: false hasContentIssue false
  • English
  • Français

Risperidone-lnduced Polydipsia and Polyphagia Associated with Galactorrhea, Abdominal Pain, and Rapid Weight Gain in an Adolescent Hispanic Female

Published online by Cambridge University Press:  07 November 2014

Khalid I. Afzal ,
David F. Briones  and
Cecilia DeVargas
Get access Rights & Permissions [Opens in a new window]

Abstract

A 15-year-old Hispanic female was started on risperidone for new-onset psychosis. The patient responded well to the gradual dose increase but developed rapid weight gain secondary to polydipsia and polyphagia. She also begain complaining of nipple discharge and griping abdominal pain on the left lower quadrant by the third week of treatment. Her prolactin level escalated to three times normal with a weight gain of 12 pounds in 16 days. Risperidone was switched to another antipsychotic. Her prolactin level then dropped to a normal level within 7 days and she lost 7 pounds in the next 2 weeks. Her abdominal pain, galactorrhea, polydipsia, and polyphagia subsided within the first few days of the cessation of risperdione.

Type
Case Report
Information
CNS Spectrums , Volume 12 , Issue 11 , November 2007 , pp. 818 - 820
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Vieweg, WV, Sood, AB, Pandurangi, A, Silverman, JJ. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? Acta Psychiatr Scand. 2005;111:177–184.CrossRefGoogle ScholarPubMed
2.Physicians' Desk Reference. 60th ed. Montvale, NJ: Medical Economics: 2006.Google Scholar
3.Safer, DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24:429–436.CrossRefGoogle ScholarPubMed
4.Bersani, G, Pesaresi, L, Orlandi, V, Gherardelli, S, Pancheri, P. Atypical antipsychotics and polydipsia: a cause or a treatment? Hum Psychopharmacol. 2007;22:103–107.CrossRefGoogle ScholarPubMed
5.Martin, A, L'Ecuyer, S. Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study. Eur Child Adolesc Psychiatry. 2002;11:129–133.CrossRefGoogle ScholarPubMed
6.Findling, RL, McNamara, NK, Gracious, BL. Antipsychotic agents: traditional and atypical. In: Martin, A, Scahill, L, Charney, DS, Leckman, JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press; 2003;328–337.Google Scholar
7.Knegtering, R, Baselmans, P, Castelein, S, Bosker, F, Bruggeman, R, van den Bosch, RJ. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry. 2005;162:1010–1012.CrossRefGoogle ScholarPubMed
8.Findling, RL, Kusumakar, V, Daneman, D, Moshang, T, De Smedt, G, Binder, C. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362–1369.CrossRefGoogle ScholarPubMed
9.Oades, RD, Daniels, R. Subclinical polydipsia and polyuria in young patients with schizophrenia or obsessive-compulsive disorder vs normal controls. Prog Neuropsychopharmacol Biol Psychiatry. 1999;23:1329–1344.CrossRefGoogle ScholarPubMed
10.Popovic, V, Doknic, M, Maric, N, et al.Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology. 2007;85:249–256.CrossRefGoogle ScholarPubMed
11.Kim, SF, Huang, AS, Snowman, AM, Teuscher, C, Snyder, SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104:3456–3459.CrossRefGoogle ScholarPubMed
12.Ratzoni, G, Gothelf, D, Brand-Gothelf, A, et al.Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. J Am Acad Child Adolesc Psychiatry. 2002;41:337–343.CrossRefGoogle ScholarPubMed
13.Mahendran, R, Liew, E, Subramaniam, M. De novo emergence of obsessive-compulsive symptoms with atypical antipsychotics in Asian patients with schizophrenia or schizoaffective disorder: a retrospective, cross-sectional study. J Clin Psychiatry. 2007;68:542–545.CrossRefGoogle ScholarPubMed
14.Faucher, S, Dardennes, R, Ghaëm, O, Guelfi, JD. Obsessive-compulsive symptoms treatment in: schizophrenia [French]. Can J Psychiatry. 2005;50:423–428.CrossRefGoogle ScholarPubMed
15.Khalili, H, Dashti-Khavidaki, S, Okhovatpour, H, Ghaeli, P. Effects of risperidone on lipid profile. Ann Pharmacother. 2007;41:899–900.CrossRefGoogle ScholarPubMed
16.Harrison-Woolrych, M, Garcia-Quiroga, J, Ashton, J, Herbison, P. Safety and usage of atypical antipsychotic medicines in children: a nationwide prospective cohort study. Drug Saf. 2007;30:569–579.CrossRefGoogle ScholarPubMed